Key Takeaways
- Eli Lilly reveals $4.5 billion in fresh capital for two Lebanon, Indiana production facilities.
- Company’s total Indiana manufacturing investment since 2020 surpasses $21 billion.
- Lebanon Advanced Therapies facility launched May 6, 2026 — marking Lilly’s inaugural genetic medicine production center.
- Lebanon API facility will manufacture tirzepatide (Mounjaro/Zepbound), orforglipron (Foundayo), and retatrutide, with 2027 launch planned.
- Completed Lebanon API site will become the nation’s largest active pharmaceutical ingredient manufacturing facility.
On May 6, 2026, Eli Lilly (LLY) revealed plans for a $4.5 billion manufacturing expansion spanning two Lebanon, Indiana production sites. Shares of LLY stock climbed 2.16%, reaching approximately $988.87 following the disclosure.
This latest capital injection pushes Lilly’s cumulative Indiana investment beyond $21 billion since 2020. Nationwide, the pharmaceutical company’s manufacturing commitments exceed $50 billion.
The funding will support two distinct Lebanon facilities. First is Lilly Lebanon Advanced Therapies, which commenced operations today. Second is Lilly Lebanon API, an upcoming active pharmaceutical ingredient production center scheduled for 2027.
The Advanced Therapies location represents Lilly’s inaugural facility dedicated exclusively to genetic medicine production. It encompasses the complete spectrum of genetic medicine platforms, spanning early-stage clinical development to full commercial-scale manufacturing.
Construction presented unique challenges. Lilly was required to engineer novel manufacturing protocols without established industry templates to reference.
The Lebanon API facility carries substantial near-term commercial significance. Production will focus on tirzepatide, the core compound in Zepbound and Mounjaro — presently the top-prescribed injectable treatments for weight management and type 2 diabetes, respectively.
Additionally, the facility will produce Foundayo (orforglipron), Lilly’s newly FDA-cleared daily oral weight loss medication. Unlike injectable alternatives, Foundayo offers flexible dosing independent of food or beverage intake.
Retatrutide, an experimental triple hormone receptor agonist undergoing advanced-phase trials for obesity and cardiometabolic conditions, rounds out the production roster.
Upon its 2027 opening, Lilly reports the Lebanon API facility will rank as America’s largest API manufacturing operation.
Substantial Regional Impact
The Lebanon complex is structured to accommodate three separate facilities. Beyond the Advanced Therapies center and API plant, a third installation — the Lilly Medicine Foundry — remains in development.
CEO David Ricks articulated the strategy plainly. “We are not just discovering the medicines of the future — we are building the world’s most advanced plants to make them,” he stated.
Indiana Governor Mike Braun praised the commitment, characterizing it as validation of the state’s leadership in life sciences and sophisticated manufacturing.
An upcoming analysis from Indiana University’s Kelley School of Business quantifies Lilly’s regional influence. The study indicates Lilly represents 70% of Indiana’s pharmaceutical economic output. Each Lilly position reportedly sustains over two additional jobs statewide, while every dollar the company invests locally generates approximately four dollars in total regional economic activity.
Manufacturing Capacity
Lilly announced intentions to initiate construction on multiple recently disclosed U.S. production facilities throughout the current year. The Lebanon campus serves as the flagship element of this domestic manufacturing initiative.
The Lebanon Advanced Therapies facility is the inaugural installation among three projected for the campus, with the API complex and Medicine Foundry following.
Lilly attributed the supplementary capital allocation to pipeline growth — particularly advanced-stage candidates including retatrutide.
